PPBT | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

905.88%

1 Month

641.67%

3 Months

424.27%

6 Months

470.51%

1 Year

60.37%

2 Year

45.90%

Key data

Stock price

$4.45

P/E Ratio

N/A

DAY RANGE

$4.02 - $4.49

EPS

N/A

52 WEEK RANGE

$0.41 - $4.72

52 WEEK CHANGE

$53.98

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-20-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$109,409

AVERAGE 30 VOLUME

$107,754

Company detail

CEO: Gil Efron
Region: US
Website: purple-biotech.com
Employees: 20
IPO year: 2015

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Purple Biotech Ltd. focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors. NT219, a small molecule that targets insulin receptor substrate substrate substrate 1 and 2, and signal transducer and activator of transcription, is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors.

PPBT - PURPLE BIOTECH LTD.